Inhibrx reports Phase 2 HNSCC data for INBRX-106 combination
Inhibrx said INBRX-106 plus pembrolizumab produced a 48.3% confirmed objective response rate and 9.6-month interim median PFS in first-line Phase 2 HNSCC, versus 26.5% and 4.9 months previously cited.
Key Highlights:Original SEC Filing: Inhibrx Biosciences, Inc. [ INBX ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain…